# BioRestorative (BRTX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/BRTX
## Company Profile
- Ticker: BRTX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 2.8028 USD
- Market cap: 9029463.447999999 USD
- Last updated: 2026-09-08
## Business Overview
BioRestorative Therapies is a regenerative medicine company focused on cell therapies and musculoskeletal repair. Its business centers on using biologic approaches to address spine and orthopedic conditions.
## Why The Stock Is Moving

As of Sep 8, 2026, BRTX closed down 5.31% at $2.80. No new same-company headline was identified in the current news window.

## Geographic Base

BioRestorative is headquartered in the United States and listed on NASDAQ. It sits in regenerative medicine and small-cap biotech.

## Business Model

The company depends on translational progress, platform validation, and financing to keep development moving. Investors typically watch preclinical or early clinical updates and the company's ability to prove a commercially relevant use case.

## Landscape Position

BioRestorative occupies a speculative regenerative-medicine niche within biotech. The stock is driven by platform credibility and the ability to turn cell therapy into a practical treatment path.

## Future Catalysts

- BioRestorative’s catalysts are regenerative medicine, spinal-disc programs, and any update that shows the platform still has a path. The company remains highly dependent on clinical progress.

## Recent News
- 2026-06-25 12:15 EST — [BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform](https://biopharmsignal.com/news/BRTX/biorestorative-therapies-announces-completion-of-brtx-100-phase-2-manufacturing--27587c89) — Source: BioRestorative
- 2026-06-18 12:15 EST — [BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth](https://biopharmsignal.com/news/BRTX/biorestorative-therapies-strengthens-leadership-with-appointment-of-healthcare-e-e42cdec1) — Source: BioRestorative
- 2026-05-26 15:00 EST — [BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data](https://biopharmsignal.com/news/BRTX/biorestorative-completes-phase-2-dosing-of-brtx-100-advancing-lead-regenerative--8f9156be) — Source: BioRestorative
- 2026-05-13 15:00 EST — [BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals](https://biopharmsignal.com/news/BRTX/biorestorative-therapies-presents-new-preclinical-data-at-isct-2026-highlighting-9821fc30) — Source: BioRestorative
- 2026-05-07 16:00 EST — [BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease](https://biopharmsignal.com/news/BRTX/biorestorative-therapies-reports-expanded-phase-2-blinded-dataset-for-brtx-100-s-3dd6ee17) — Source: BioRestorative